You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Human and equine cardiovascular endocrinology: beware to compare

Van Der Vekens, Nickya; Hunter, Ingridb; Goetze, Jens P.c; Decloedt, Anneliesa; De Clercq, Dominiquea; van Loon, Gunthera

Cardiovascular Endocrinology:
doi: 10.1097/XCE.0000000000000009
Review articles
Abstract

Cardiac biomarkers such as troponins and natriuretic peptides are routinely used in human medicine for the evaluation of myocardial damage and heart failure. Recently, these markers have also been introduced in veterinary medicine. Comparison between human and equine cardiac biomarker studies show important species differences, which can partly be explained by variations in physiology or pathophysiology. Most important are physiological differences in heart rate, cardiovascular response to exercise, food and water intake, and molecular elimination in plasma. Pathological differences are even more prominent. In humans, troponins and natriuretic peptides are mostly used for the diagnosis of acute coronary syndromes and heart failure. These cardiac entities, however, are rare in horses. In this species, cardiac biomarkers are rather proposed for the assessment of valvular or myocardial disease. In conclusion, these species differences corroborate that extrapolation of cardiac biomarker data should always be performed with caution and species-specific data should be applied whenever possible.

Author Information

aDepartment of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Ghent, Belgium

bDepartment of Veterinary Disease Biology, Faculty of Health and Medical Science

cDepartment of Clinical Biochemistry, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark

Correspondence to Nicky Van Der Vekens, DVM, Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Ghent, Belgium Tel: +32 9 264 75 84; fax: +32 9 264 75 96; e-mail: nicky.vandervekens@ugent.be

Received January 31, 2013

Accepted May 28, 2013

© 2013Wolters Kluwer Health Lippincott Williams Wilkins

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.